Whats Happening? Novavax Inc. (Nasdaq: NVAX) is getting attention lately as investors debate the potential of the company’s respiratory syncytial virus (RSV) vaccination “ResVax”, a proposed 1:20 … [Read more...] about NVAX At A Glance
MS Number 1 Pick For April 2019
This stock has been at the top of our buy list since February. Despite Adma Biologics (Nasdaq: ADMA) gaining 78% in the past few months the share price still has room for near-term growth. Luckily, … [Read more...] about MS Number 1 Pick For April 2019
Corbus Pharmaceuticals Has A New Board Member
A press release today from Corbus Pharmaceuticals (Nasdaq: CRBP) announced the addition of Rachelle Jaques to the board of directors. After this appointment CRBP's board consists of 7 highly qualified … [Read more...] about Corbus Pharmaceuticals Has A New Board Member
Two Biotech Stocks We Are Watching For Entry
The past two weeks have been tumultuous for the markets and biotech was not insulated. With the sell-off comes opportunities to buy cheap and sell into the recovery which I believe began last week. … [Read more...] about Two Biotech Stocks We Are Watching For Entry
ADMA Presents Potential Entry For Investors On The Sideline
Today Adma Biologics (Nasdaq: ADMA) sold off ~10% closing at $3.50. Most of us already in Adma were not phased. Personally, I saw this as a healthy pullback. Since February 1st ADMA has gained 25% … [Read more...] about ADMA Presents Potential Entry For Investors On The Sideline
GALT Updates NASH-RX Presentation
GALT has updated their NASH-CX presentation. Click here to view the form 8-K and presentation. On March 06, 2019 GALT filed registration statements of a rights offering of common stock and … [Read more...] about GALT Updates NASH-RX Presentation
Buying The Panic
For this move, we are buying the panic. Insys Therapeutics (Nasdaq: INSY) has dropped significantly in the past few weeks. The downtrend started following INSY's fourth-quarter 2018 earnings … [Read more...] about Buying The Panic
More Near-Term Downside For KPTI
KPTI's data does not adequately demonstrate a treatment benefit from Oral Selinexor plus low-dose dexamethasone in Penta-Relapsed/Refractory Multiple Myeloma (RRMM).Serious adverse events during … [Read more...] about More Near-Term Downside For KPTI
Interview with SCYNEXIS Following Positive Interim-Results from Phase 3 Open-Label FURI Study
Preface The following was the result of discussion and collaboration between MS Money Moves and SCYNEXIS (Nasdaq: SCYX) Chief Financial Officer Eric Francois. We are thankful for his time and … [Read more...] about Interview with SCYNEXIS Following Positive Interim-Results from Phase 3 Open-Label FURI Study
Intercept Announces Positive Top-Line Data From Phase 3 Study In Liver Fibrosis
On the heels of Gilead's (NYSE: GILD) disappointing phase 3 data readout in compensated cirrhosis from NASH (F4); Intercept Pharmaceutical (NYSE: ICPT) announced today positive results from their … [Read more...] about Intercept Announces Positive Top-Line Data From Phase 3 Study In Liver Fibrosis
